Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Prime Medicine, Inc.'s (PRME) shares have risen 16.4% in the past three months compared with the industry's growth of 10.9%. The stock has also outperformed the sector and the S&P 500. PRME Outperforms Industry, Sector & S&P 500 Prime Medicine is deploying its proprietary gene editing technology, Prime Editing platform, to develop a new class of differentiated one-time curative genetic therapies. While the approach is interesting, the company's ability to have sufficient cash leeway to conduct its R&D progr ...